242 filings
Page 3 of 13
8-K
2vj7g0o8u42f eo5a
10 Nov 22
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
5:00pm
8-K
jmdmc lh0tahn4279jza
27 Oct 22
Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC
4:15pm
8-K
3rkiumo61ab
16 Aug 22
Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
4:21pm
8-K
g38h64e 554lkh74
27 Jul 22
Other Events
7:30am
8-K
2t2i zxuw2nfij
22 Jul 22
Entry into a Material Definitive Agreement
4:20pm
8-K
o23v tjqgq
28 Jun 22
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
4:13pm
8-K
qwphh8321 3ll6
23 May 22
Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer
5:42pm
8-K
e80vsdx7xgkh 27b
16 May 22
Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
12:00am
8-K
27o5deo8en0a
4 May 22
Other Events
4:33pm
8-K
3805it
18 Apr 22
Diffusion Pharmaceuticals Announces 1-for-50 Reverse Stock Split as Part of Nasdaq Compliance Plan
4:25pm
8-K
s1uf8j5gu80f
12 Apr 22
Diffusion Pharmaceuticals Completes Dosing in Altitude Trial
9:08am
8-K
ubzdr38ks1bbc 4dp
8 Apr 22
Diffusion Pharmaceuticals Announces New Date for Previously Announced Special Meeting of Stockholders
5:04pm
8-K
6nyrjvrzuee0xo zyc69
21 Mar 22
Diffusion Pharmaceuticals Reports 2021 Financial Results and Provides Business Update
4:26pm
8-K
0vidot
18 Mar 22
Entry into a Material Definitive Agreement
5:14pm
8-K
vqoi6 t92
21 Dec 21
Other Events
4:06pm
8-K
d4ebe 1uqu
24 Nov 21
Other Events
4:15pm
8-K
4y1pitk99s 3yylp
10 Nov 21
Diffusion Pharmaceuticals Reports Third Quarter Financial Results
8:01am
8-K
51ru0e
5 Nov 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:43pm
8-K
hb296veh
12 Oct 21
Regulation FD Disclosure
7:04am
8-K
jordlo1qsa
13 Sep 21
Diffusion Pharmaceuticals Issues Letter to Shareholders
4:09pm